Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
EARLY_PHASE1
15 participants
INTERVENTIONAL
2014-05-31
2016-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effectiveness of N-Acetylcysteine (NAC) in Treating Cocaine Dependent Individuals - 1
NCT00218491
Effectiveness of N-acetylcysteine in Treating Cocaine Dependent Individuals - 1
NCT00136825
NAC as a Potential Treatment for Methamphetamine Dependence
NCT01063205
Effects of N-acetylcysteine on Brain Chemistry and Behavior in Cocaine Abusers (NAC)
NCT01392092
Efficacy of N-acetylcysteine on the Craving Symptoms of Abstinent Hospitalized Patients With Cocaine Addiction
NCT03423667
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
BASIC_SCIENCE
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Placebo
Subjects will be maintained on oral placebo.
Cocaine
The pharmacodynamic effects of cocaine will be determined during maintenance on placebo and n-acetylcysteine.
Placebo
n-Acetylcysteine
Subjects will be maintained on oral n-acetylcysteine.
Cocaine
The pharmacodynamic effects of cocaine will be determined during maintenance on placebo and n-acetylcysteine.
n-Acetylcysteine
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Cocaine
The pharmacodynamic effects of cocaine will be determined during maintenance on placebo and n-acetylcysteine.
n-Acetylcysteine
Placebo
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Current cigarette smoker
Exclusion Criteria
* Current or past histories of substance abuse or dependence that are deemed by the study physicians to interfere with study completion
* History of serious physical disease, current physical disease, impaired cardiovascular functioning, chronic obstructive pulmonary disease, history of seizure or current or past histories of serious psychiatric disorder that in the opinion of the study physician would interfere with study participation will be excluded from participation
* Females not currently using effective birth control
* Contraindications to cocaine or n-acetylcysteine
* History of schizophrenia in first degree relative
18 Years
55 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Institute on Drug Abuse (NIDA)
NIH
University of Kentucky
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
William Stoops
Associate Professor
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Kentucky Laboratory of Human Behavioral Pharmacology
Lexington, Kentucky, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.